Skip to main content
. 2017 Mar 27;8:155. doi: 10.3389/fphar.2017.00155

Table 4.

Changes in the transcript level of ABCC2 and RRM1 when treated with gemcitabine and/or the other fragment hits.

Treatment Gene fold changes
ABCC2 STDEV RRM1 STDEV
GEM 100 nM GEM 12.27 ±0.34 4.43 ±0.13
MBF D1 MBF D1 only 0.66*** ±0.14 1.11*** ±0.17
MBF D1 + 100 nM GEM 1.33*** ±0.33 2.07*** ±0.16
MBF B1 MBF B1 only 0.49*** ±0.08 1.22*** ±0.12
MBF B1 + 100 nM GEM 1.21*** ±0.53 2.77*** ±0.11
MBF 10 MBF 10 only 1.00*** ±0.23 1.76*** ±0.14
MBF 10 + 100 nM GEM 0.68*** ±0.05 1.56*** ±0.08
MBF 11 MBF 11 only 1.09*** ±0.09 1.04*** ±0.11
MBF 11 + 100 nM GEM 0.93*** ±0.15 1.88*** ±0.20
MBF 12 MBF 12 only 0.65*** ±0.13 1.39*** ±0.09
MBF 12 + 100 nM GEM 1.25*** ±0.19 2.11*** ±0.15
MBF 20 MBF 20 only 0.7*** ±0.06 1.43*** ±0.11
MBF 20 + 100 nM GEM 1.13*** ±0.05 2.02*** ±0.12

A 2-sided T-test was performed to assess statistical significance vs. GEM alone, P-values being encoded as * < 0.05, ** < 0.01,

***

< 0.001.